Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in BFLY.

← Back to Free Index

BFLY

Analysis as of: 2026-11-07

Butterfly Network, Inc.

Butterfly sells handheld whole-body ultrasound probes, cloud workflow software, and embedded ultrasound technology to clinicians, health systems, and development partners.

ai enterprise healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

A handheld imaging platform at an inflection point

The upside case rests on turning a real device lead into governed workflow, compliance, and partner economics that grow faster than probe units. Recent execution improved that path, but the market still needs proof that Embedded and new care settings are durable rather than lumpy.

Analysis

Thesis

Butterfly can grow from a handheld ultrasound vendor into a software-defined imaging platform if it turns its chip advantage into governed workflow, home-care deployment, and repeatable Embedded licensing; the upside is driven more by revenue quality and breadth than by probe units alone.

Last Economy Alignment

Butterfly benefits as AI makes image acquisition guidance, documentation, and remote supervision more useful, while its hardware and regulated workflow layers remain harder to commoditize than software alone. The score is capped by large OEM bundling risk, customer concentration, and the need to prove value capture beyond probe sales.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.5x (from 5 most recent analyses)

Reasoning

The upside case is that Butterfly becomes a governed imaging workflow company with meaningful partner licensing, not just a probe seller. If enterprise deployments, home and community care, and Embedded revenue diversify the base, investors can still value it as a growth medtech platform. I keep the outcome below blue-sky software valuations because large OEM competition, concentration, and dilution risk remain material.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is conversion, not invention. Butterfly already has a credible product and improving mix, but the 2031 case depends on turning early proof points into diversified, repeatable, higher-margin revenue before larger imaging vendors neutralize the differentiation. Customer concentration, possible dilution, and any slip in the 2027 product cycle are the biggest threats to the multiple.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On October 29, 2026, third-quarter results beat guidance, gross margin reached 73%, and full-year 2026 guidance was raised.
On October 29, 2026, FedRAMP moved from expectation to achieved status, making the federal and VA pipeline more credible.
As of the October 29, 2026 update, Home & Community Care shifted from buildout to implementation, with first revenue expected in November or Q4 2026.
The October 29, 2026 shelf and up to 150.0 ATM improved financing flexibility but also increased dilution overhang.

Thesis update

The core thesis is unchanged, but the evidence improved: trust and compliance moved from promise to proof, and non-probe monetization paths look more concrete than they did previously.

Forecast update

A better mix trajectory and stronger operating proof support somewhat more upside, but concentration and financing optionality still keep the outcome bounded.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.42

They control a real chip-and-workflow stack that gets more useful as AI makes scanning help, documentation, and remote oversight cheaper. The risk is that bigger imaging vendors bundle similar handheld tools before Butterfly makes its workflow and trust layer essential.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$11.17

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research